

*Comparison of Vascular Endothelial Growth Factor-A (VEGF-A) Level in Pleural Fluid of Patients with Malignant and Nonmalignant Pleural Effusion*

**Wahyuni Hariyanto, Laksmi Wulandari, Isnu Pradjoko & Gatot Soegiarto**

Indian Journal of Surgery

ISSN 0972-2068


Indian J Surg

DOI 10.1007/s12262-020-02204-z



Your article is protected by copyright and all rights are held exclusively by Association of Surgeons of India. This e-offprint is for personal use only and shall not be self-archived in electronic repositories. If you wish to self-archive your article, please use the accepted manuscript version for posting on your own website. You may further deposit the accepted manuscript version in any repository, provided it is only made publicly available 12 months after official publication or later and provided acknowledgement is given to the original source of publication and a link is inserted to the published article on Springer's website. The link must be accompanied by the following text: "The final publication is available at [link.springer.com](http://link.springer.com)".

Ukraine: visit [Nature news](#) for the latest coverage and [click here for Springer Nature's statement](#)



# Indian Journal of Surgery

 [Editorial board](#) [Aims & scope](#)

The Indian Journal of Surgery offers peer-reviewed coverage of all types of surgery. The Journal publishes Original articles, Points of technique, Review articles, Case reports, Letters, Images and brief biographies of influential teachers and surgeons.

The Journal spans General Surgery, Pediatric Surgery, Neurosurgery, Plastic Surgery, Cardiothoracic Surgery, Vascular Surgery, Rural Surgery, Orthopedic Surgery, Urology, Surgical Oncology, Radiology, Anaesthesia, Trauma Services, Minimal Access Surgery, Endocrine Surgery, GI Surgery, ENT, Colorectal Surgery, surgical practice and research.

— [show all](#)

## Editor-in-Chief

Sandeep Kumar

## Publishing model

Hybrid (Transformative Journal). [How to publish with us, including Open Access](#)

**0.656 (2020)**

Impact factor

**0.873 (2020)**

Five year impact factor

Ukraine: visit [Nature news](#) for the latest coverage and [click here](#) for Springer Nature's [statement](#)



# Indian Journal of Surgery

[Journal home](#) > [Editors](#)

## Editors

### Editor-in-Chief

Dr. Sandeep Kumar

MS FRCS (Edinburgh) PhD (Wales) MMSc (Newcastle)

Chairman/Editor-in-chief

Consultant Surgeon, Scientist and Epidemiologist

Professor and Founder Director, All India Institute of Medical Sciences, Bhopal, India

### Immediate Past Editor-in-Chief

Dr. Chintamani

### Editor 2019-2024

Dr. Mallika Tewari

### Nominated Editor 2019-2021

Dr. Satish Dharap

### Editorial Board 2019-2024

Dr. Arunima Verma

Dr. CS Rajan

Dr. Debarshi Sharma

Dr. Debajit Ghanta

Dr. G Laxmana Sastry

Dr. Vikram Kate

### **Nominated Editorial Board 2019-2021**

Dr. Kaushik Bhattacharya

Dr. MD Ibrarullah

Dr. M Bhaskar

Dr. M Kanagaval

Dr. Ramen Goel

### **Research Design & Statistical Committee**

Dr. Anamika Pandey

Dr. Anurag Srivastava

Dr. Arun Chaturvedi

Dr. GG Agarwal

Dr. L Jeyaseelan

### **Editorial Advisors**

Dr. HS Shukla

Dr. Satish K Shukla

### **Overseas Editorial Advisors**

Dr. Arun Dhir

Dr. Ismail Jatoi

Dr. RE Mansel

Dr. Vijayshil Gautam

### **Associate Editors**

Dr. Dilip Gupta

Dr. G Raghavendra Prasad

Dr. K Lakshman

Dr. M S Senthil Kumar

Dr. Raja Kalayarasan

Dr. Ramanuj Mukherjee

Dr. Sandeep C Sabnis

Dr. S George Barreto

Dr. Sudeep R Shah

Dr. Surajeet Bhattacharya

### **Sectional Editors**

Dr. Amit Agarwal

Dr. Ashok Kumar Gupta

Dr. Dhairyasheel Savant

Dr. Kalpesh Jani

Brig (Dr) PP Rao

Dr. Ramesh Ardhanari

Dr. Ramesh S

Dr. Rajashekar Mohan

Dr. S P Somashekhar

Dr. Usha R Dalal

Dr. Winston Noronha

Dr. YM Fazil Marickar

### **Governing Council ASI 2021**

President – Dr. Abhay Dalvi

President Elect – Dr. G Siddhesh

Immediate Past President - Dr. P Raghuram

Honorary Secretary – Dr. Sanjay Kumar Jain

Honorary Treasurer – Dr. CRK Prasad

Director Academic Council – Dr. Santhosh John Abraham

Director Social Welfare Council – Dr. Dilip S. Gode

Secretary Head Quarter – Dr. PV Ramana Murthy

### **Executive Committee (2019-21)**

Dr. Ganni Bhaskara Rao

Dr. Santa Rao, Assam

Dr. Manoj K Choudhury, Bihar

Dr. Ashok Kumar Sinha

Dr. Bindey Kumar

Dr. NP Narain, Gujarat

Dr. Gunvant H Rathod  
Dr. Kaushik Gajjar  
Dr. Pankaj R Modi  
Dr. Rajan B Patel, Haryana  
Dr. Kartar Singh Yadav  
Dr. Shiv Shanker Bhardwaj, Jammu & Kashmir  
Dr. Nasib Chand Digra, Jharkhand  
Dr. Jugal Kishore Chaudhary  
Dr. Sunil Kumar, Karnataka  
Dr. Ashok S Godhi  
Dr. G Siddesh  
Dr. K Rajgopal Shenoy, Kerala  
Dr. CJ Varghese  
Dr. Mohammed Ismail  
Dr. P Rajan  
Dr. RC Sreekumar, Madhya Pradesh  
Dr. Achal Gupta  
Dr. Amitabh Goel, Maharashtra  
Dr. AM Quraishi  
Dr. Pratapsinh A Varute  
Dr. Pravin R Suryawanshi  
Dr. Roysuneel V Patankar, New Delhi  
Dr. CK Durga  
Dr. KN Srivastava  
Dr. Pawanindra Lal, Odisha  
Dr. Banabihari Mishra  
Dr. Sreejoy Patnaik, Punjab  
Dr. Deepak Chawla  
Dr. US Dhaliwal, Rajasthan  
Dr. Bhanwar Lal Yadav  
Dr. Om Prabha  
Dr. Raj Kewal Jenaw, Tamil Nadu  
Dr. BKC Mohanprasad  
Dr. G Chandrasekar  
Dr. Maruthu D Pandian  
Dr. SR Subrammanian, Telangana

Dr. G Kanka Raju

Dr. L Sridhar, Uttar Pradesh

Dr. Anand K Mishra

Dr. Amit Srivastava

Dr. Nikhil Singh

Dr. Prabol Neogi, West Bengal

Dr. Dhruvajyoti Bhaumik

Dr. Makhan Lal Saha

Dr. Prabir Bijoy Kar

Dr. Sanjay De Bakshi

### **Editorial Office**

Dr. Eti Dinesh

Senior Editor - Clinical Medicine

Springer Nature India Private Limited

7th Floor, Vijaya Building, 17 Barakhamba Road

New Delhi

## For authors

---

[Submission guidelines](#)

[Ethics & disclosures](#)

[Open Access fees and funding](#)

[Contact the journal](#)

Submit manuscript

## Explore

---



[Online first articles](#)[Volumes and issues](#)[Sign up for alerts](#)

### **Publish with us**

[Authors & Editors](#)[Journal authors](#)[Publishing ethics](#)[Open Access & Springer](#)

### **Discover content**

[SpringerLink](#)[Books A-Z](#)[Journals A-Z](#)[Video](#)

### **Other services**

[Instructors](#)[Librarians \(Springer Nature\)](#)[Societies and Publishing Partners](#)[Advertisers](#)[Shop on Springer.com](#)

### **About Springer**

[About us](#)[Help & Support](#)[Contact us](#)

[Press releases](#)

[Impressum](#)

## **Legal**

[General term & conditions](#)

[California Privacy Statement](#)

[Rights & permissions](#)

[Privacy](#)

[How we use cookies](#)

[Manage cookies/Do not sell my data](#)

[Accessibility](#)

Not logged in - 103.109.155.124

Not affiliated

---

## **SPRINGER NATURE**

© 2022 Springer Nature Switzerland AG. Part of [Springer Nature](#).



Ukraine: visit [Nature news](#) for the latest coverage and [click here](#) for Springer Nature's [statement](#)



# Indian Journal of Surgery

[Journal home](#) > [Volumes and issues](#) > Volume 83, issue 1

Search within journal

## Volume 83, issue 1, February 2021

88 articles in this issue

### Acute Critical Care Course for Clinicians—Why, What, and How?

Akshay Kumar, Richa Aggarwal & Ajay Kumar Sharma

Editorial | Published: 01 February 2021 | Pages: 1 - 2

### Qualitative Research in Surgical Disciplines: Need and Scope

Jitendra Kumar Meena, Ashish Jakhetiya & Arun Pandey

Review Article | Published: 16 May 2020 | Pages: 3 - 8



### Hepatic Hemangioma Treatment Using Microwave Coagulation Therapy—a Systematic Review

Zhi Zhang, Jia-zhi Li & Hong-Mian Li




Review Article | Published: 21 May 2020 | Pages: 9 - 16

## Strategies for Optimizing the Use of PPE During Surgery in COVID-19 Pandemic: Rapid Scoping Review of Guidelines

Vikesh Agrawal, Sanjay Kumar Yadav ... Dhananjaya Sharma

Review Article | Published: 06 January 2021

Pages: 17 - 27



## Surgical Management of Breast Cancer in Turkey: a 30-Year Single-Center Retrospective Study of 2531 Patients

Fatih Can Karaca, Ali Pusane ... Ceyhun Oral

Original Article | Published: 16 August 2019

Pages: 28 - 37



## Surgery Combined with Long-Term Imatinib Treatment for Patients with Recurrent or Metastatic Gastrointestinal Stromal Tumors


Chunhui Shou, Qing Gao ... Jiren Yu

Original Article | Published: 07 May 2020 | Pages: 38 - 42

## Adequacy of Case Notes in a Tertiary Care Hospital —an Audit

Divya T K &amp; Lakshman K


Original Article | Published: 07 May 2020 | Pages: 43 - 47



## Laparoscopic and Robotic Surgery for Rectal Cancer—Comparative Study Between Two Centres

Audrius Dulskas, Mahdi Albandar ... Nam Kyu Kim

Original Article | Published: 08 May 2020 | Pages: 48 - 54



## Effectiveness and Feasibility of Limberg and Karydakis Flap in Recurrent and Complicated Pilonidal Sinus Disease

Amr Abdel Hameed Elhiny, Doaa Ali Saad & Mohamed Sadek Farahat

Original Article | Published: 08 May 2020 | Pages: 55 - 60



## Thinned Pedicle Deep Inferior Epigastric Perforator (DIEP) Flap for Scrotal Reconstruction

Baoqiang Song, Zhaoxiang Zhang ... ZhangQiang Tuo

Original Article | Published: 08 May 2020 | Pages: 61 - 65



## Necrotising Soft Tissue Infection in the Twenty-First Century—a Clinical and Microbiological Spectrum Analysis

Balachandra Menon, Murali Krishna ... Sandeep Mehrotra

Original Article | Published: 08 May 2020 | Pages: 66 - 71



## Total Laparoscopic Approach for Rectal Cancer Resection—a Novel Technique and Review of the Literature

Shailesh Puntambekar, Mihir Chitale ... Mangesh Panse


Original Article | Published: 09 May 2020 | Pages: 72 - 78



## Predictive Factors and Effects of Replaced Rectorectal Intussusception on Functional Outcomes in Patients with Rectoanal Intussusception Who Have Undergone Laparoscopic Ventral Rectopexy

Naoki Oka, A. Tsunoda ... H. Kusanagi

Original Article | Published: 11 May 2020 | Pages: 79 - 86



## Desarda Repair for Incarcerated Groin Hernia: A

## Case Series Analysis

A. Sanna, L. Felicioni ... F. Polistina


Original Article | Published: 11 May 2020 | Pages: 87 - 91



## C-Reactive Protein to Albumin Ratio: A Reliable Marker in Gastric Cancer Surgery

Ozlem Zeliha Sert, Hilmi Bozkurt ... Mustafa Duman

Original Article | Published: 12 May 2020 | Pages: 92 - 99



## A LIP Abdominal Tuberculosis Classification System for Surgery

Zhi Wang, Jin-Chen Liu ... Yong Zhang

Original Article | Published: 12 May 2020 |

Pages: 100 - 106



## A Single-Stage Reconstruction of Maxillectomy Defects with Temporalis Muscle Flap—Revisiting the Past

Pallvi Kaul, Mahendra Pal Singh ... Pankaj Kumar Garg

Original Article | Published: 12 May 2020 |

Pages: 107 - 113




## The Role of Portoenterostomy with Aggressive Hilar Dissection in Biliary Tract Tumors: Report of Case Series and Review of the Literature

Osman Nuri Dilek, Feyyaz Güngör ... Fatma Hüsnüye Dilek

Original Article | Published: 12 May 2020 |

Pages: 114 - 120



## Day Care Appendectomy Is Safe in Young Patients with Uncomplicated Early Presentation

Mauricio Gonzalez-Urquijo, Diego A. Guajardo-Nieto ... Gerardo Gil-Galindo

Original Article | Published: 12 May 2020 | Pages: 121 - 125

## Foreign Bodies in the Urinary Bladder and its Management: a Single Centre Experience from North India

Ankur Bansal, Manoj Kumar ... Siddharth Singh

Original Article | Published: 12 May 2020 |

Pages: 126 - 131



## Comparison of Vascular Endothelial Growth Factor-A (VEGF-A) Level in Pleural Fluid of Patients with Malignant and Nonmalignant Pleural Effusion

Wahyuni Hariyanto, Laksmi Wulandari ... Gatot Soegiarto

Original Article | Published: 13 May 2020 |

Pages: 132 - 138



## Local Temporal Island Flap Combined with Orbicularis Oculi Muscle Flap for Reconstruction of the Lower Anterior Eyelid

YiChun Ding, XiaoJing Li ... Fei Zhu

Original Article | Published: 14 May 2020 |

Pages: 139 - 143




## Dorsal Pancreatic Artery—a Study of Its Detailed Anatomy for Safe Pancreaticoduodenectomy

T Tatsuoka, T Noie ... Y Harihara

Original Article | [Open Access](#) |

Published: 15 May 2020 | Pages: 144 - 149



## Evaluation of Outcome of Parotidectomy

Erika Tamie Saito, Luiza Soares de Melo Costa ... Rogério Aparecido Dedititis




Original Article | Published: 15 May 2020 | Pages: 150 - 154

## Early Laparoscopic Cholecystectomy Has an Advantage over Antecedent Drainage for Grade II/III Acute Cholecystitis

Yasunori Otowa, Hidehiro Sawa ... Daisuke Kuroda

Original Article | Published: 16 May 2020 |

Pages: 155 - 159




## Comparison of POMPP Scoring System with PULP Score, Boey Score, and ASA Scoring Systems to Predict Mortality in Peptic Perforation

Shalu Gupta, Somendra Bansal ... Pranav Vasudev Gwalani

Original Article | Published: 16 May 2020 |

Pages: 160 - 164



## Is Ghost Ileostomy an Effective Method in Various Indications for Colorectal Surgery?

Serkan Zenger, Bulent Gurbuz ... Dursun Bugra


Original Article | Published: 16 May 2020 | Pages: 165 - 169

## Simple Peripheral Blood Cell Parameters to Predict Prognosis in Non-Small Cell Lung Cancer

Muhammet Sayan, Aykut Kankoc ... Abdullah Irfan Tastepe

Original Article | Published: 16 May 2020 |

Pages: 170 - 175



## An Indigenous Virtual Reality-Based Simulator—a Tool in Surgical Training

Ajay Raghunath Aspari, Vibha Ramesh &amp; Krishnaswamy Lakshman



Original Article | Published: 18 May 2020 |

Pages: 176 - 182

## Early Surgery in Trauma Patients Is a Key Performance Indicator of Outcome—A Case Series Analysis

Dinesh Kumar Bagaria, Amit Gupta ... Sushma Sagar


Original Article | Published: 18 May 2020 | Pages: 183 - 187

## Evaluation of Predictive Value of P-POSSUM Score in Patients Operated for Acute Abdomen and Comparison of Scoring at Admission and Pre-operatively

Nitin Garg & Arpit Bandi

Original Article | Published: 18 May 2020 |

Pages: 188 - 193



## A Comparative Study of Clinicopathological Profile and Surgical Outcomes of Endoscopic (Bilateral Axillo-Breast Approach) Versus Conventional Total Thyroidectomy for Thyroid Tumors

Nitish Gupta, Gyan Chand ... Saroj K. Mishra


Original Article | Published: 19 May 2020 | Pages: 194 - 200

## Effect of Duration of CO<sub>2</sub> Pneumoperitoneum on Post Laparoscopic Gastrointestinal Dysmotility: an Experimental Study

Basil Badarudeen, B. K. Varghese ... C. S. Naidu

Original Article | Published: 19 May 2020 |

Pages: 201 - 205



## Video-Assisted Thoracoscopic Surgery for the First Episode of Primary Spontaneous Pneumothorax

Cumhur Murat Tulay & Sadık Yaldiz



Original Article | Published: 20 May 2020 |

Pages: 206 - 210

## Predictors of Leak After Colorectal Anastomoses: a Case Series Analysis

Shiv Kishor, Harpal Singh ... Anil Kumar


Original Article | Published: 20 May 2020 | Pages: 211 - 216

## Surgical Treatments for Advanced Cutaneous Melanoma

YiJun Xia, DongSheng Cao ... Juan Xie

Original Article | Published: 21 May 2020 |

Pages: 217 - 223



## Learning Laparoscopic Cholecystectomy: a Surgical resident's Insight on Safety and Training During the Initial 151 Cases

Yun Kyung Jung, Dongho Choi &amp; Kyeong Geun Lee

Original Article | Published: 21 May 2020 |

Pages: 224 - 229




## Relationship Among Three Different Viruses and Primary Lung Cancer

Cheng Shen, Jie Ren &amp; Guowei Che

Original Article | Published: 21 May 2020 |

Pages: 230 - 236



## Chronic Non-specific Upper Abdominal Pain of Median Arcuate Ligament Syndrome: Laparoscopic Treatment

Sameer A. Rege, Amiteshwar Singh &amp; Abhay N. Dalvi



Original Article | Published: 21 May 2020


Pages: 237 - 243

## Can Great Saphenous Vein Diameter Be Correlated with Clinical Severity Scores and Quality of Life in Indian Population?

Arunjeet KK &amp; Manoj Kumar

Original Article | Published: 21 May 2020

Pages: 244 - 247




## Randomized Control Clinical Trial of Overnight Fasting to Clear Fluid Feeding 2 Hours Prior Anaesthesia and Surgery

Yayati Joshi &amp; Silky Dhamija

Original Article | Published: 22 May 2020

Pages: 248 - 254



## Laparoscopic Totally Extraperitoneal Hernia Repairs: a Case Series Analysis

Yasin Kara &amp; Hakan Bolukbasi


Original Article | Published: 20 June 2020 | Pages: 255 - 260

## Effect of Sleeve Gastrectomy on the Neutrophil-to-Lymphocyte Ratio, the Platelet-to-Lymphocyte Ratio, Platelet Counts, and Mean Platelet Volumes

Muhammed Rasid Aykota, Sevda Yilmaz ... Selda Simsek


Original Article | Published: 29 June 2020

Pages: 261 - 267



## Non-COVID Surgical Emergency During the Nationwide Lockdown due to Corona Pandemic: a Critical Appraisal

Rahul, Alka Verma ... Om Prakash Sanjeev



Original Article | Published: 10 August 2020


Pages: 268 - 272

## Fore Foot Pain: Morton Neuroma Surgery—Tips for Surgeons

Bulent Karslioglu, Metin Uzun & Fatma Tokat

Original Article | Published: 03 October 2020

Pages: 273 - 276




## Elective Gastrointestinal Surgery in COVID Times

Deeksha Kapoor, Azhar Perwaiz ... Adarsh Chaudhary

Original Article | Published: 22 October 2020

Pages: 277 - 283



## Persistent Hyperparathyroidism: How Many Cases Can Be Prevented

Osman Toktas

Original Article | Published: 01 February 2021 | Pages: 284 - 288

## Early Results of Totally Implantable Central Venous Access Port Insertion Through a Supraclavicular Approach


Du-Young Kang & Tae Yun Oh

Surgical Techniques and Innovations | Published: 21 May 2020 | Pages: 289 - 292

## Hemocholecyst: Is Surgery Required?

Iraklis Perysinakis, Mikela-Rafaella Siligardou ... Georgios Stamatakis


Case Report | Published: 06 May 2020 | Pages: 293 - 295



## Giant Ectopic Retroesophageal Parathyroid Adenoma Excised Via Cervical Incision: a Case Report

C. Nastos, I. Sotirova ... M. Peppas

Case Report | Published: 06 May 2020 | Pages: 296 - 298

[← Previous](#)

1

[2](#)[Next →](#)

## For authors

[Submission guidelines](#)[Ethics & disclosures](#)[Open Access fees and funding](#)[Contact the journal](#)[Submit manuscript](#)

## Explore

[Online first articles](#)[Volumes and issues](#)[Sign up for alerts](#)

**SPRINGER NATURE**

© 2022 Springer Nature Switzerland AG. Part of [Springer Nature](#).



# Comparison of Vascular Endothelial Growth Factor-A (VEGF-A) Level in Pleural Fluid of Patients with Malignant and Nonmalignant Pleural Effusion

Wahyuni Hariyanto<sup>1</sup> · Laksmi Wulandari<sup>2</sup> · Isnu Pradjoko<sup>1</sup> · Gatot Soegiarto<sup>3</sup>

Received: 4 September 2019 / Accepted: 9 April 2020

© Association of Surgeons of India 2020

## Abstract

Malignant pleural effusion (PE) is a complication that often occurs in advanced cancer. The sensitivity of pleural fluid cytology is reported to vary from 30 to 90%; therefore, the process is less clinically practical in certain conditions. Thus, special biomarkers are needed to distinguish malignant PE and nonmalignant PE. The aim of this study is to compare the level of vascular endothelial growth factor-A (VEGF-A) in pleural fluid of patients with that in malignant and nonmalignant PE. Participants were divided into 2 groups: 19 patients with nonmalignant PE, and 34 patients with malignant PE. Both groups underwent pleural puncture procedures and were examined for VEGF-A levels. Statistical analysis was performed using the paired test or Mann–Whitney test. The ROC curve was employed to determine the VEGF-A cut-off value in malignant PE. The VEGF-A level in pleural fluid of malignant PE group was  $1940.77 \pm 1016.54$  pg/mL, while the nonmalignant group was  $178.16 \pm 192.01$  pg/mL ( $p < 0.001$ ; 95% CI). The average VEGF-A level in malignant PE group with positive anatomic pathology results was  $2036.69 \pm 1008.15$  pg/mL, and negative was  $1855.51 \pm 1045.35$  pg/mL ( $p = 0.612$ ; 95% CI). The cutoff value for VEGF-A level in pleural fluid for the diagnosis of malignant PE was 416.60 pg/mL with a sensitivity and specificity of 85.29% and 84.22% respectively. Examination of VEGF-A level in pleural fluid can be considered as a means of supporting the diagnosis of malignant PE.

**Keywords** Malignant · Nonmalignant · Pleural effusion · VEGF-A

## Introduction

Malignant pleural effusion (PE) is the most common complication found in advanced cancer. Malignant PE cases are estimated to occur in more than 150,000 people each year in the USA, and patients with complications or metastases from lung cancer account for half of the cases [1]. Epidemiological

studies showed there are 22% of malignant PE and 42% of exudate PE. Epidemiological studies in Western countries found three major causes of PE, namely malignant PE, heart failure, and parapneumonic effusion [2]. Malignant PE originates from primary pleural malignancies (e.g., mesothelioma) or from pleural metastases from extrapleural malignancies. Lung cancer is the most common cause of malignant PE with an incidence of 25–52%. Metastatic adenocarcinoma is a histopathological type of tumor that most often causes malignant PE [3].

The diagnosis of malignant PE often faces problems. Current definitive method for diagnosing malignant PE is by performing cytology examination on pleural fluid. In general, the specificity of this procedure is high, but its sensitivity is reported to vary from 30 to 90%. Therefore, the process is less clinically practical in certain conditions. If the cytological examination is negative, a 7–12% diagnosis of malignant PE can be made with pleural biopsy. Medical thoracoscopy is the next diagnostic option in cases of exudative PE with a suspected cause of malignancy. However, around 10% of PE cases fail to establish the etiologic diagnosis after thoracoscopy, and more

✉ Laksmi Wulandari  
laksmi.wulandari@fk.unair.ac.id

<sup>1</sup> Department of Pulmonology and Respiratory, Faculty of Medicine, Universitas Airlangga – Dr. Soetomo General Academic Hospital, Jl. Mayjen Prof. Dr. Moestopo no. 6-8, Airlangga, Gubeng, Surabaya 60286, Indonesia

<sup>2</sup> Thoracic Oncology Division, Department of Pulmonology and Respiratory, Faculty of Medicine, Universitas Airlangga – Dr. Soetomo General Academic Hospital, Surabaya 60286, Indonesia

<sup>3</sup> Clinical Immunology Division, Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga – Dr. Soetomo General Academic Hospital, Surabaya 60286, Indonesia



than 20% cannot be diagnosed after pleural fluid cytology and pleural biopsy [4]. The medical thoracoscopy procedure is not always available at all health facilities, and the examination costs are quite high. More than 15% of patients with exudative PE cannot be diagnosed with an etiological diagnosis after pleural cytology and biopsy. Therefore, it is necessary to find a fluid marker that can distinguish malignant and nonmalignant PE [2].

The pathophysiology of malignant PE formation includes mechanisms of pleural fluid drainage related to obstruction of blood vessels and pulmonary as well as pleural lymphatic systems. Lymphatic tissue obstruction is caused by the spread of tumors in the parietal pleural stomata and mediastinal lymph node which results in obstruction of fluid in the pleural cavity. Barriers to fluid flow from the pleural cavity are not the only cause of PE formation [2, 3]. Malignant PE does not always occur in some tumors causing lymphatic obstruction [5]. Tumor cells secrete several vasoactive mediators that contribute to the formation of malignant PE by increasing the rate of leakage of blood vessels. Increased vascular permeability results in excessive plasma leakage. The main mediators that play roles in vascular leakage are vascular endothelial growth factor (VEGF) and angiopoietin [6]. Vascular endothelial growth factor-A (VEGF-A) is one of the cytokines that play a role in the formation of malignant PE [7].

VEGF-A has two main functions, namely increasing vascular permeability, and serving as the most important angiogenic factor in various physiological and pathological conditions including infection. Bacterial infection causes an acute inflammatory response associated with neutrophil influx, increased vascular permeability, and edema. A study of neutrophil stimulation *in vitro* showed that bacterial infection also induces VEGF-A secretion [8]. In addition to acute bacterial infections, an increase in VEGF level is detected in granulomatous diseases, such as tuberculosis. Alveolar macrophage stimulation in the tuberculosis infection process secretes various cytokines including VEGF. In tuberculosis patients, there is an increase in serum VEGF levels compared with those of inactive tuberculosis patients [9].

Biomarkers of the nature of VEGF are involved in normal physiological processes and in many diseases, including inflammatory conditions and are essential for angiogenesis that is a prerequisite for growth or healing. Pleural fluid contains VEGF receptors, and many cells like macrophages mesothelial cells, infiltrating inflammatory cells, cancer cells, adjacent airway epithelial cells, type II alveolar cells, alveolar macrophages, infiltrating neutrophils, and eosinophils of the lung—all of which may contribute to VEGF accumulation in pleural fluid [10, 11].

In the study, Matsuyama et al. [9] measured subsets of VEGF in duplicate serum samples and characterized the soluble isoforms VEGF 165 and VEGF 121. Their assays were reported to be sensitive to the presence of just 9 pg/mL and

were not affected by the presence of other cytokines like platelet-derived growth factor (PDGF) and other homologous markers. They found high titers in active pulmonary tuberculosis and related the falling titers over a period of 6 months, with an improvement of PT. They also studied the Presence of VEGF in macrophages of the lung specimens by histochemistry. Biomarkers thus can sometimes help in monitoring the clinical course as is well known with others such as CRP, ProCal, etc. In a controlled blinded prospective study, Shu et al. [4] estimated VEGF in both serum and pleural fluid simultaneously and evaluated them against the standard of clinical evaluation by pleural cytology and pleural biopsy. They found that after “using receiver operating characteristic analysis” the cutoff values of VEGF levels in PE and serum to be 959.25 pg/mL and 212.36 pg/mL respectively for diagnosis of malignant PE (sensitivity 47%, 69% and specificities of 98% and 86% respectively). In other words as a diagnostic test, it is inadequate and at best can be an expensive test to aid a diagnosis awaiting confirmation by other means.

This study measured VEGF-A level in pleural fluid of patients with malignant PE related to lung cancer, and patients with nonmalignant PE related to the infection process, as well as assessing the difference between the two. The aim of this study is to determine the potential of VEGF-A level in pleural fluid as a biomarker in the diagnosis of malignant PE and provide a pathophysiological picture of malignant PE related to lung cancer and nonmalignant PE related to infection.


## Methods

Participants in this study were patients with PE in Dr. Soetomo General A Hospital, Surabaya, Indonesia. The inclusion criteria were patients aged > 16 years old with malignant PE diagnosis (lung cancer) and patients diagnosed with nonmalignant PE (pneumonia and/or lung tuberculosis). Patients with malignant PE receiving chemotherapy and empyema patients were excluded from this study. The participants filled the consent form before the study. The diagnosis of lung cancer used standard diagnosis in Dr. Soetomo General Academic Hospital, Surabaya, Indonesia [12, 13].

A cross-sectional method was employed with a consecutive sampling technique. The study was conducted in Dr. Soetomo General Academic Hospital from August to December 2018. A total of 53 participants were divided into two groups: malignant PE group consisting of 34 patients and non-malignant PE group consisting of 19 patients (Fig. 1). All participants were examined for VEGF-A level in pleural fluid, followed by a comparative analysis between the two groups. This study was reviewed by the ethical committee and has received approval (0609/KEPK/lx/2018) before its conduct.

The examination of VEGF-A level was conducted following the thoracentesis procedure. The pleural fluid was

Fig. 1 Subject sampling



obtained by firstly determining the position of the lung where PE took place. Then, a needle was inserted to a point in the midaxillary line in the 6th, 7th, or 8th intercostal [14]. In the case of minimum PE, the thoracentesis procedure was assisted with ultrasonography guidance [15]. Pleural fluid was obtained with a volume of 20 cc, placed in a tube and centrifuged for 10 min. The supernatant was extracted and stored in a fridge at 18–25 °C. The VEGF-A serum was measured using a Sandwich Enzyme-Linked Immunosorbent Assay (ELISA; system R&D, USA), and was read at 450 nm in a 680XR microplate reader (Biorad, USA) [16].

The results were presented in the form of mean  $\pm$  standard deviation (SD). Statistical analysis was performed using the paired *t* test or Mann–Whitney test (CI 95%;  $p < 0.05$ ). Kolmogorov–Smirnov test was employed to examine data distribution. Receiver operating characteristics (ROC) was employed to determine the cutoff value of VEGF-A in malignant PE patients. The ROC was obtained by measuring sensitivity and specificity values of malignant PE. IBM SPSS Statistics software version 23.0 (IBM Corp., Armonk, NY, USA) was used for statistical analysis.

## Results

### Characteristics of the Participants

Participants were divided into two groups: malignant PE (34 patients; 54.15%) and nonmalignant PE (19 patients; 35.85%). Most participants were female patients, consisting of 52.64% in nonmalignant group and 55.88% in malignant group. The average age of the participants was  $53.58 \pm 13.53$  years old, ranging from 16 to 81 years old. Most participants in nonmalignant group attended senior high school (36.84%), followed by elementary school (26.31%). On the other hand, most participants in malignant group were elementary school graduates (38.23%), followed by senior high

school graduates (32.35%). In terms of occupation, housewives consisted of 26.31% in nonmalignant group and 44.12% in malignant group. In terms of smoking status, most participants were non-smokers (32 patients, 60.38%; Table 1).

For the diagnosis of participants, out of 34 malignant PE patients, 29 patients were diagnosed with adenocarcinoma (85.29%), 1 patient with adenosquamous carcinoma (2.94%), 3 patients with squamous cell carcinoma (8.82%), and 1 patient with small-cell carcinoma (2.94%). In the non-malignant group, there were 17 patients with tuberculous PE (89.47%), 1 patient with pneumonia (5.26%), and 1 patient with pneumonia + tuberculosis (5.26%).

### Results of Pleural Fluid Analysis

The average number of cells in the nonmalignant group ( $2433.11 \pm 2463.30/\mu\text{l}$ ) was higher than the malignant group ( $1876.82 \pm 1808.00/\mu\text{l}$ ). On the other hand, the average number of mononuclear (MN) in the nonmalignant group ( $69.84 \pm 32.09\%$ ) was lower than the malignant group ( $75.17 \pm 28.65\%$ ). The average protein content in the two groups showed nearly similar values. Statistics comparisons of the cell, MN, and protein amount were not significant. A significant comparison between nonmalignant and malignant groups was found for glucose content ( $p = 0.024$ ) and lactic acid dehydrogenase/LDH ( $p = 0.025$ ; Table 2).

The pathology examination of pleural fluid in terms of cytology in malignant group showed 13 positive patients (38.23%) and 21 negative patients (61.77%). On the other hand, pathology anthology examination on cell block found 18 negative participants (52.94%) and 16 positive participants (47.06%).

### VEGF-A Level in Pleural Fluid

The average VEGF-A level in pleural fluid of malignant and non-malignant groups were  $1940.77 \pm 1016.54$  pg/mL and

**Table 1** Characteristics of participants

Characteristic	Non-malignant (%; n = 19)	Malignant (%; n = 34)	p
Sex			
Male	9 (47.36)	15 (44.12)	0.287
Female	10 (52.64)	19 (55.88)	
Age (year)			
Mean ± SD	47.74 ± 14.99	56.85 ± 11.63	0.089
Min–max	16–71	33–81	
Education			
Elementary school	5 (26.31)	13 (38.23)	–
Junior high school	3 (15.79)	3 (8.82)	
Senior high school	7 (36.84)	11 (32.35)	
Non-degree	4 (21.06)	7 (20.60)	
Diploma/Bachelor degree			
Occupation			
Civil servant	1 (5.26)	6 (17.65)	–
Housewife	5 (26.31)	15 (44.12)	
Seller	2 (10.52)	6 (17.65)	
Office staff	3 (15.79)	1 (2.94)	
Construction worker	1 (5.26)	1 (2.94)	
Factory worker	1 (5.26)	0 (0.00)	
Workshop worker	0 (0.00)	1 (2.94)	
Farmer	1 (5.26)	2 (5.88)	
Nurse	1 (5.26)	0 (0.00)	
Student	2 (10.52)	0 (0.00)	
Driver	1 (5.26)	0 (0.00)	
Unemployed	1 (5.26)	2 (5.88)	
Brinkman index			
Mild	1 (5.26)	0 (0.00)	–
Moderate	7 (36.84)	4 (11.76)	
Severe	1 (5.26)	8 (23.53)	
Non-smoker	10 (52.63)	22 (64.71)	

178.16 ± 192.01 pg/mL respectively ( $p < 0.001$ ; Fig. 2). In the malignant group with positive anatomic pathology values, the VEGF-A level was 2036.69 ± 1008.15 pg/mL, while the VEGF-A level in negative anatomic pathologies was 1855.51 ± 1045.35 pg/mL ( $p = 0.612$ ).

**Table 2** Analysis of pleural fluid


	Non-malignant (n = 19)	Malignant (n = 34)	p
Cell amount (/μl)	2433.11 ± 2463.30	1876.82 ± 1808.00	0.351
MN (%)	69.84 ± 32.09	75.17 ± 28.65	0.911
Glucose (mg/dl)	85.63 ± 31.99	119.06 ± 57.51	0.024*
Protein (g/dl)	4.62 ± 1.36	4.66 ± 1.30	0.903
LDH (U/l)	675.89 ± 786.76	1303.32 ± 1378.10	0.025*

MN, mononuclear; LDH, lactate dehydrogenase; \*significant < 0.05

### Cut-off, Sensitivity, and Specificity Values of VEGF-A in Pleural Fluid of Patients with Malignant Pleural Effusion

The cut-off value lay in the area under 0.963, where the intersection point between sensitivity and specificity was at point 22 with a VEGF-A value of 416.60 pg/mL (Fig. 3). The VEGF-A sensitivity and specificity values in this study were 85.29% and 84.22% respectively. Positive predictive value (PPV) of VEGF-A in this study was the number of samples in malignant PE group with VEGF-A levels ≥ cutoff values among all samples with VEGF-A levels ≥ cutoff values. Meanwhile, the negative predictive value (NPV) of VEGF-A in this study was the number of samples in nonmalignant PE group with VEGF-A levels < cutoff values among all samples with VEGF-A levels < cutoff values. The values of PPV and NPV VEGF-A in this study were 93.55% and 76.19% respectively.

**Fig. 2** VEGF-A level in pleural fluid of patients with malignant and nonmalignant pleural effusion ( $p < 0.001$ ; CI 95%)




## Discussion

This study found that adenocarcinoma was the major profile causing malignant PE. Some studies suggested that most malignant PE occurs in adenocarcinoma [17]. Malignant PE is an early clinical sign that is generally found in lung adenocarcinoma patients, with a high EGFR mutation level particularly in exon 21 L858R mutation [18].

This study found significant differences in PE fluid between the two groups, especially in glucose and LDH levels. These significant differences might be due to tuberculosis related effusion in most participants in the nonmalignant group. Measurement of pleural fluid glucose levels ( $< 60$  mg/dL)

could indicate a diagnosis of parapneumonic PE, malignancy, rheumatoid disease, or tuberculous pleurisy [19]. Malignant PE and tuberculosis-related PE have a similar characteristic of pleural fluid analysis profile that is exudative lymphocytic predominant. In addition, glucose level in tuberculosis-related PE was found to be at a lower level of 4.33 mmol/L compared with malignant PE of 6.22 mmol/L [20]. Lactic acid dehydrogenase is a marker of non-specific inflammation that increases in both tuberculosis and cancer. In cancer, a higher LDH increase generally indicates a wider pleural inflammation process and the presence of blood cells in the pleural cavity [17].

The standard diagnosis of malignant PE is the presence of malignant cells in pleural fluid cytology. The specificity of pleural fluid cytology is generally high, but its sensitivity is reported between 30 and 90% [21]. Therefore, a biomarker is needed to help the diagnosis of malignant PE. In this study, the participants of malignant PE with positive pleural fluid anatomy pathology were 47.06% with cell block examination. This number was higher compared with the results of positive anatomic pathology with pleural fluid cytology examination of 38.23%. Cell block method has a higher sensitivity and can maintain tissue patterns, and the block can be stored for further staining or immunohistochemistry. Shivakumarswamy's study compared the interpretation of pleural fluid anatomical pathology samples with cytology and cell block smears. The cell block showed cellular features with glandular patterns, cell layers, clusters, and cell balls. On the other hand, the cytology smear method showed the pattern of a spread-out single cell. The cell block method can also maintain the structure of the nucleus, cytoplasm, cell membranes, and chromatin details. Furthermore, it can increase the diagnosis of anatomic pathology by 15% compared with that of pleural fluid cytology. This study found an increase in the diagnosis of pleural fluid anatomy pathology by 9% [22].



**Fig. 3** ROC curve of VEGF-A level in pleural fluid

In this study, malignant PE had significantly higher VEGF-A pleural fluid level than patients with nonmalignant effusion. Several previous studies stated that VEGF-A levels were consistently and significantly higher in malignant PE than non-malignant PE. A study conducted by Jia et al. compared the value of VEGF-A serum in lung cancer, gastric cancer, and non-cancerous diseases. The study found that VEGF-A level in lung cancer pleural fluid was 457.54 pg/mL, while non-malignant PE was 124.48 pg/mL [7]. Kim et al., in their study, compared pleural fluid VEGF levels in PE related to lung cancer and PE related to tuberculosis. The study obtained VEGF level in malignant PE was  $2091.47 \pm 1624.80$  pg/mL; and in tuberculosis group,  $1291.05 \pm 110.53$  pg/mL [17].

The VEGF-A values of participants with positive pleural fluid anatomy pathology were higher than those with negative pleural fluid anatomy pathology, although the difference was not statistically significant ( $p > 0.05$ ). Patients with various types of lung cancer, especially non-small cell carcinoma (NSCC), generally have elevated VEGF expression in cancer cells. Several local cancer factors such as hypoxia, numerous growth, and hormonal factors can contribute to the induction of VEGF expression in cancer cells. Growth factors include epidermal growth factor, transforming growth factor, and insulin-like growth factor. Increased VEGF in malignant PE can also be related to the interaction of VEGF and VEGFR that stimulates cancer cells and mesothelial cells to secrete VEGF. Increased VEGF-A level in pleural fluid is not only related to the presence of malignant cells in PE, but also related to local cancer factors, mesothelial cells in malignant PE conditions that also secrete VEGF-A, and interactions between VEGF and VEGFR [7, 17, 23].

The VEGF-A value of  $\geq 416.60$  pg/mL that correctly clarified patients with malignant PE was in fact around 85.29%. On the other hand, the VEGF-A value of  $< 416.60$  pg/mL that confirmed patients with PE instead of tuberculosis, according to the finding was 84.22%. A study by Jia et al. used median levels of VEGF-A level in pleural fluid with a cutoff value of 406.19 pg/mL, followed by survival time analysis, and obtained that patients with pleural fluid VEGF-A level of  $> 406.19$  pg/mL had a relatively shorter survival time rate although not statistically significant ( $p = 0.066$ ) [7]. In Zhou et al.'s study, the comparison of VEGF pleural fluid in malignant PE and pleural tuberculosis effusion resulted in sensitivity and specificity data of 71% and 61% respectively [24]. The difference in sensitivity and specificity values of this study compared with that of other studies could be caused partly by the differences in the characteristics and number of samples.

This study found that positive predictive value and negative predictive value of VEGF-A level in pleural fluid were 93.55% and 76.19% respectively. These values indicated that the VEGF-A value of  $\geq 416.60$  pg/mL could correctly predict tuberculosis PE patients at 93.55%, while the VEGF-A value of

$< 416.60$  pg/mL could predict that a person does not suffer from a nonmalignant PE at 76.19%.

The limitation of this study is the diagnosis in the impure nonmalignant pleural effusion group using bacteriological examination results, but non-bacteriological assessment based on clinical symptoms, radiological results, and/or participant pleural fluid analysis. In addition, the grouping of pleural fluid types does not use Light's criteria [25].

## Conclusion

This study found a significant comparison between VEGF-A level in pleural fluid of patients with malignant and nonmalignant PE, where the VEGF-A level was higher in malignant PE than nonmalignant. There were no significant differences in VEGF-A levels in malignant PE patients with positive and negative anatomic pathology results. The sensitivity and specificity of VEGF-A level in pleural fluid for the diagnosis of malignant PE were 85.29% and 84.22% respectively, with a cutoff value of 416.60 pg/mL. The VEGF-A examination in pleural fluid can be considered as a means of supporting the diagnosis of malignant PE.

**Acknowledgments** We thank Ms. Rossellini Ngiono B. Sc for her dedicated time to review and proofread our manuscript.

**Author's Contribution** All authors contributed toward data analysis, drafting and revising the paper, gave final approval of the version to be published and agree to be accountable for all aspects of the work.

## Compliance with Ethical Standards

**Conflict of Interest** The authors declare that they have no conflict of interest.

## References

1. Asamura H (2010) Principles and practice of lung cancer. Lippincott Williams & Wilkins, Philadelphia
2. Thomas R, Kalomenidis I, Jett J, Lee YC (2016) Textbook of pleural diseases. Taylor & Francis
3. Haas AR, Sterman DH, Musani AI (2007) Malignant pleural effusions: management options with consideration of coding, billing, and a decision approach. *Chest* 132(3):1036–1041. <https://doi.org/10.1378/chest.06-1757>
4. Shu J, Sun G, Liu H, Liu J (2007) Clinical utility of vascular endothelial growth factor in diagnosing malignant pleural effusions. *Acta Oncol* 46(7):1004–1011
5. Spella M, Giannou AD, Stathopoulos GT (2015) Switching off malignant pleural effusion formation-fantasy or future? *J Thorac Dis* 7(6):1009–1020. <https://doi.org/10.3978/j.issn.2072-1439.2015.05.20>
6. Yano S, Shinohara H, Herbst RS, Kuniyasu H, Bucana CD, Ellis LM, Fidler IJ (2000) Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by

- human lung cancer cells. *Am J Pathol* 157(6):1893–1903. [https://doi.org/10.1016/S0002-9440\(10\)64828-6](https://doi.org/10.1016/S0002-9440(10)64828-6)
7. Jia L, Du Y, Li T, Lv Y, Wang Y, Zhang Y, Zhou X, Liu W (2015) Differential expression of vascular endothelial growth factor-A, -C and -D for the diagnosis and prognosis of cancer patients with malignant effusions. *Oncol Lett* 10(2):667–674. <https://doi.org/10.3892/ol.2015.3305>
  8. Van Der Flier M, Coenjaerts F, Kimpen JL, Hoepelman AM, Geelen SP (2000) Streptococcus pneumoniae induces secretion of vascular endothelial growth factor by human neutrophils. *Infect Immun* 68(8):4792–4794. <https://doi.org/10.1128/iai.68.8.4792-4794.2000>
  9. Matsuyama W, Hashiguchi T, Matsumuro K, Iwami F, Hirotsu Y, Kawabata M, Arimura K, Osame M (2000) Increased serum level of vascular endothelial growth factor in pulmonary tuberculosis. *Am J Respir Crit Care Med* 162(3):1120–1122
  10. Fiorelli A, Vicidomini G, Di Domenico M, Napolitano F, Messina G, Morgillo F, Ciardiello F, Santini M (2011) Vascular endothelial growth factor in pleural fluid for differential diagnosis of benign and malignant origin and its clinical applications. *Interact Cardiovasc Thorac Surg* 12(3):420–424. <https://doi.org/10.1510/iccvs.2010.250357>
  11. Koniari I, Koletti B, Apostolakis E (2011) Vascular endothelial growth factor with tumour growth factor-beta, endostatin, proteinases or cytokines might be useful for differential diagnosis of pleural effusions. *Interact Cardiovasc Thorac Surg* 12(3):424–425. <https://doi.org/10.1510/iccvs.2010.250357A>
  12. Merinda V, Soegiarto G, Wulandari L (2020) T790M mutations identified by circulating tumor DNA test in lung adenocarcinoma patients who progressed on first-line epidermal growth factor receptor-tyrosine kinase inhibitors. *Lung India* 37(1):13–18. [https://doi.org/10.4103/lungindia.lungindia\\_182\\_19](https://doi.org/10.4103/lungindia.lungindia_182_19)
  13. Wulandari L, Soegiarto G, Febriani A, Fatmawati F, Sahrin (2020) Comparison of detection of epidermal growth factor receptor (EGFR) gene mutation in peripheral blood plasma (liquid biopsy) with cytological specimens in lung adenocarcinoma patients. *Indian J Surg Oncol*. <https://doi.org/10.1007/s13193-020-01046-1>
  14. Kalifatidis A, Lazaridis G, Baka S, Mpoukovinas I, Karavasilis V, Kioumis I, Pitsiou G, Papaiwannou A, Karavergou A, Tsakiridis K (2015) Thoracentesis: from bench to bed. *J Thorac Dis* 7(1):S1–S4
  15. Cao W, Wang Y, Zhou N, Xu B (2016) Efficacy of ultrasound-guided thoracentesis catheter drainage for pleural effusion. *Oncol Lett* 12(6):4445–4448
  16. Gupta PK, Prabhakar S, Sharma S, Anand A (2011) Vascular endothelial growth factor-a (VEGF-A) and chemokine ligand-2 (CCL2) in amyotrophic lateral sclerosis (ALS) patients. *J Neuroinflammation* 8(1):47
  17. Kim H-R, Kim B-R, Park R-K, Yoon K-H, Jeong E-T, Hwang K-E (2017) Diagnostic significance of measuring vascular endothelial growth factor for the differentiation between malignant and tuberculous pleural effusion. *Tohoku J Exp Med* 242(2):137–142. <https://doi.org/10.1620/tjem.242.137>
  18. Wu S-G, Yu C-J, Tsai M-F, Liao W-Y, Yang C-H, Jan I-S, Yang P-C, Shih J-Y (2013) Survival of lung adenocarcinoma patients with malignant pleural effusion. *Eur Respir J* 41(6):1409–1418
  19. Light RW (2007) Pleural diseases. 5 edn. Lippincott Williams & Wilkins
  20. Porcel JM, Vives M (2003) Differentiating tuberculous from malignant pleural effusions: a scoring model. *Med Sci Monit* 9(5):CR175–CR180
  21. Takahashi S (2011) Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy. *Biol Pharm Bull* 34(12):1785–1788. <https://doi.org/10.1248/bpb.34.1785>
  22. Shivakumarswamy U, Arakeri SU, Karigowdar MH, Yelikar B (2012) Diagnostic utility of the cell block method versus the conventional smear study in pleural fluid cytology. *J Cytol* 29(1):11–15. <https://doi.org/10.4103/0970-9371.93210>
  23. Chen Y, Mathy NW, Lu H (2018) The role of VEGF in the diagnosis and treatment of malignant pleural effusion in patients with non-small cell lung cancer (review). *Mol Med Rep* 17(6):8019–8030. <https://doi.org/10.3892/mmr.2018.8922>
  24. Zhou WB, Bai M, Jin Y (2009) Diagnostic value of vascular endothelial growth factor and endostatin in malignant pleural effusions. *Int J Tuberc Lung Dis* 13(3):381–386
  25. Porcel JM (2013) Identifying transudates misclassified by Light's criteria. *Curr Opin Pulm Med* 19(4):362–367. <https://doi.org/10.1097/MCP.0b013e32836022dc>

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**ETHICAL COMMITTEE IN HEALTH RESEARCH  
Dr. SOETOMO GENERAL HOSPITAL SURABAYA**

**“ ETHICAL CLEARANCE ”**

**0609/KEPK/IX/2018**

**THE ETHICAL COMMITTEE OF Dr. SOETOMO GENERAL HOSPITAL SURABAYA HAS BEEN REVIEWED THE SUBMITTED RESEARCH PROPOSAL THOROUGHLY, AND BY THIS LETTER, THE ETHICAL COMMITTEE IN HEALTH RESEARCH HEREBY DECLARES THE RESEARCH BY THE TITLE OF:**

**“ Comparison of Vascular Endothelial Growth Factor-A (VEGF-A) Level in Pleural Fluid of Patients with Malignant and Nonmalignant Pleural Effusion ”**

**PRINCIPAL INVESTIGATOR : Wahyuni Hariyanto, dr**

**SUPPORTING RESEARCHERS : 1. Dr. Laksmi Wulandari, dr., Sp.P (K), FCCP  
2. Isnu Pradjoko, dr., Sp.P (K)  
3. Dr. Gatot Soegiarto, dr., Sp.PD., KAI, FINASIM**

**UNIT/INSTITUTION/ RESEARCH LOCATION : RSUD Dr. Soetomo**

**IS DECLARED ETHICAL WORTHY**

**Valid from : 12/09/2018 to 12/09/2019**

**Surabaya, 12 September June 2018**

**CHAIRMAN**

**(Dr. Elizeus Hanindito, dr., Sp.An, KIC, KAP)**

**NIP/19511007 197903 1 002**

**\* ) This certificate is declared valid if it has obtained the original seal from the Health Research Ethics Committee**







# Source details

## Indian Journal of Surgery

Scopus coverage years: from 1945 to 1952, 1958, 1965, 1967, from 1973 to 1983, from 2004 to Present

Publisher: Springer Nature

ISSN: 0972-2068 E-ISSN: 0973-9793

Subject area: Medicine: Surgery

Source type: Journal

CiteScore 2020

0.6



SJR 2020

0.183



SNIP 2020

0.442



[View all documents >](#)

[Set document alert](#)

[Save to source list](#) [Source Homepage](#)

[CiteScore](#) [CiteScore rank & trend](#) [Scopus content coverage](#)

### Improved CiteScore methodology



CiteScore 2020 counts the citations received in 2017-2020 to articles, reviews, conference papers, book chapters and data papers published in 2017-2020, and divides this by the number of publications published in 2017-2020. [Learn more >](#)

CiteScore 2020 ▼

$$0.6 = \frac{359 \text{ Citations 2017 - 2020}}{598 \text{ Documents 2017 - 2020}}$$

Calculated on 05 May, 2021

CiteScoreTracker 2021 ⓘ

$$0.5 = \frac{439 \text{ Citations to date}}{916 \text{ Documents to date}}$$

Last updated on 06 March, 2022 • Updated monthly

### CiteScore rank 2020 ⓘ

Category	Rank	Percentile
Medicine		
— Surgery	#320/422	24th

[View CiteScore methodology >](#) [CiteScore FAQ >](#) [Add CiteScore to your site](#)

Ads by Google

Stop seeing this ad Why this ad?

### Indian Journal of Surgery

<b>COUNTRY</b> India 	<b>SUBJECT AREA AND CATEGORY</b> Medicine Surgery	<b>PUBLISHER</b> Springer India	<b>H-INDEX</b> <b>21</b>
<b>PUBLICATION TYPE</b> Journals	<b>ISSN</b> 00195690, 09722068, 09739793	<b>COVERAGE</b> 1945-1952, 1958, 1965, 1967, 1973-1983, 2004-2020	<b>INFORMATION</b> <a href="#">Homepage</a> <a href="#">How to publish in this journal</a>

#### SCOPE


The Indian Journal of Surgery is the official publication of the Association of Surgeons of India that considers articles in all fields of surgery. Issues are published bimonthly in the months of February, April, June, August, October and December. The journal publishes Original articles, Points of surgical technique, Review articles, Case reports, Letter to editor, Images in surgery and Teachers and surgeons from the past - A short (up to 500 words) bio sketch of a revered teacher or surgeon whom one holds in esteem. The journal provides a platform for the publication of high-quality clinical and experimental studies, thereby documenting recent advances and new developments in all fields of surgery. The Journal is an academic initiative of the Association of Surgeons of India, which has more than 17,000 member surgeons in India alone. The main objective of the journal is to provide a platform for surgeons from India and Abroad to exchange ideas, propagate the advancement of science and art of surgery and promote friendship among surgeons in India and globally. Over the years this Journal has been able provide a powerful platform for Surgeons in bringing-out up-to-date scientific information to the community. Indian Journal of Surgery focuses on General surgery and certain aspects of Pediatric Surgery, Surgical Oncology, Trauma Services, Minimal Access Surgery, Endocrine Surgery, GI Surgery, Colorectal Surgery that are relevant to a general surgeon. Each submitted article is reviewed by more than 500 professional surgeons from across the globe based on their surgical specialization. The journal aims to continue its mission of being the ambassador of surgical research and innovations from India, and also serve as a platform of surgeons from across the world to share their research findings.

Join the conversation about this journal

#### Quartiles

#### FIND SIMILAR JOURNALS

1 <b>BMC Surgery</b> QBR <b>84%</b> similarity	2 <b>Asian Journal of Surgery</b> TWR <b>82%</b> similarity	3 <b>Acta Chirurgica Belgica</b> QBR <b>76%</b> similarity	4 <b>Turkish Journal of Surgery</b> TUR <b>74%</b> similarity	5 <b>International Surgery</b> UBA <b>74%</b> similarity
--	---	--	---	--



Metrica based on Scopus® data as of April 2021

Indian Journal of Surgery

Q4 Surgery

0.18

powered by scimago.com

Show this widget in your own website

Just copy the code below and paste within your html code:

<https://www.scimago.com>

SCImago Graphica

Explore, visually communicate and make sense of data with our new free tool.

Get it

**C** **Clement Tirta** 2 years ago

Dear,  
Indian Journal of Surgery

I would like to publish my journal about a polytrauma case report. I would like to have more information about the registration and the price for it. Hope for your information soon.

Sincerely,  
Clement Tirta, MD

← reply

**Melanie Ortiz** 2 years ago

Dear Clement,  
thank you for contacting us.  
Unfortunately, we cannot help you with your request, we suggest you visit the journal's homepage (See submission/author guidelines) or contact the journal's editorial staff, so they could inform you more deeply.  
Best Regards, SCImago Team

SCImago Team

**R** **Rafik Shalaby** 2 years ago

Fees  
for manuscript

← reply